Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer.
Future Oncol
; 17(3): 291-299, 2021 Jan.
Article
em En
| MEDLINE
| ID: mdl-32996811
ABSTRACT
Aim:
Study first-line (1L) treatment patterns and economic outcomes among patients with advanced metastatic gastric cancer (GC) and esophageal cancer (EC). Materials &methods:
Newly diagnosed patients with systemic GC and EC treatments were identified between 1 January 2011 and 31 July 2017; costs were presented as per patient per month (PPPM) basis.Results:
Study included 392 GC and 436 EC patients. Most frequently used 1L regimens were 5-fluorouracil (5-FU) + oxaliplatin (22.5%) and epirubicin + cisplatin + 5-FU (ECF)/ECF modifications (21.9%) in patients with GC; and carboplatin + paclitaxel (29.6%) and 5-FU + oxaliplatin (11.5%) in EC patients. Mean all-cause costs were US$16,242 PPPM for GC, and $18,384 PPPM for EC during 1L treatment.Conclusion:
GC and EC were resource intensive and costly. High costs and short treatment durations underscored a gap in care in 1L treatment.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
/
Neoplasias Esofágicas
/
Aceitação pelo Paciente de Cuidados de Saúde
/
Custos de Cuidados de Saúde
Tipo de estudo:
Health_economic_evaluation
/
Observational_studies
/
Risk_factors_studies
Aspecto:
Implementation_research
Limite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2021
Tipo de documento:
Article